Form 4: PTC Therapeutics Exec Reports Stock Transactions

PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, reported the acquisition of restricted stock units and stock options, alongside the exercise and sale of common stock, all under a Rule 10b5-1 plan.

Summary

• Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT), reported several equity transactions.
• On January 2, 2026, Boulding was granted 17,000 Restricted Stock Units (RSUs) at a price of $0, which are scheduled to vest in four equal annual installments beginning January 2, 2027.
• Also on January 2, 2026, Boulding received a grant of 42,500 stock options with an exercise price of $76.74, vesting over four years, with 25% on January 2, 2027, and 6.25% every three months thereafter starting April 2, 2027.
• On January 5, 2026, Boulding exercised 2,266 stock options at an exercise price of $39.42. These options were originally granted on January 5, 2023.
• Concurrently on January 5, 2026, Boulding sold a total of 2,266 shares of common stock in multiple transactions at weighted average prices of $74.92 (1,123 shares), $76.1 (1,035 shares), and $76.79 (108 shares).
• All transactions on January 5, 2026, were executed pursuant to a pre-arranged Rule 10b5-1 plan adopted on December 4, 2024.
• Following these reported transactions, Boulding beneficially owns 120,901 shares of common stock directly and 9,063 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing is a factual report of insider transactions, including routine equity grants and sales under a pre-planned program, which does not inherently convey positive or negative sentiment regarding the company's performance or outlook.

Positives

• Grant of 17,000 Restricted Stock Units (RSUs) on January 2, 2026, at a price of $0, aligning executive incentives with long-term company performance.
• Grant of 42,500 stock options on January 2, 2026, with an exercise price of $76.74, providing further long-term incentive for the executive.

Negatives

• Sale of 2,266 shares of common stock on January 5, 2026, at weighted average prices ranging from $74.92 to $76.79, which reduces direct ownership, although these sales were pre-planned.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent market risks associated with holding or selling equity securities.

Future Outlook

The 17,000 Restricted Stock Units granted on January 2, 2026, are scheduled to vest in four equal annual installments, commencing on January 2, 2027. The 42,500 stock options granted on January 2, 2026, will vest over four years, with 25% vesting on January 2, 2027, and an additional 6.25% vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.

Industry Context

This Form 4 filing details routine insider transactions, including equity grants and sales under a pre-arranged plan, which are common practices for executive compensation and liquidity in the biotechnology and pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and liquidity events. The grants of RSUs and stock options align the executive's interests with long-term shareholder value creation. Sales under a 10b5-1 plan are generally expected and do not typically signal a change in management's outlook.

Next Steps

• Continued vesting of 17,000 Restricted Stock Units, with the first installment on January 2, 2027.
• Continued vesting of 42,500 stock options, with the first 25% vesting on January 2, 2027, and subsequent quarterly vesting.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, insider trading, stock options, restricted stock units, executive compensation, stock sale, Rule 10b5-1 plan